ONCOLYTIC VIRUS ENCODING PD-1 BINDING AGENTS AND USES OF THE SAME

• US 20150250837A1
• Filed: 09/19/2013
• Published: 09/10/2015
• Est. Priority Date: 09/20/2012
• Status: Abandoned Application

• Current Assignee: VIP Life Science Ltd.
• Original Assignee: Morningside Technology Ventures Ltd.
• Inventors: Nolin, Westley B., Ng, Shi Chung, Dinges, Jason R., Chan, Gerald L.
• Application Number:
  US14/429,673
• Publication Number:
  US 20150250837A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 35/761 Adenovirus
• CPC Class Codes: A61K 35/763 Herpes virus
• CPC Class Codes: A61K 35/768 Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C12N 2710/10032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/10043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/10071 Demonstrated in vivo effect
• CPC Class Codes: C12N 2710/16632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/16643 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/16671 Demonstrated in vivo effect
• CPC Class Codes: C12N 2710/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/24171 Demonstrated in vivo effect
• CPC Class Codes: C12N 2810/859 from immunoglobulins
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present disclosure concerns the use of oncolytic viruses for the treatment of cancer. In particular, the use of a herpes simplex virus, a vaccinia virus, or an adenovirus containing a gene encoding a PD-1 binding agent, such as a scFv polypeptide, to achieve a particular degree of oncolysis is described. In some embodiments, the oncolytic virus expressing the PD-1 binding agent is effective at inducing immune responses that kill cancer cells at distant sites from the primary tumor. An oncolytic virus can also be engineered to be less toxic or damaging to non-cancer cells by mutation or modification of gene products such that the alterations render the viruses better able to infect the host, less toxic, and/or better able to selectively infect cancer cells.

Claims

1. A recombinant oncolytic virus comprising a heterologous nucleic acid sequence encoding an anti-PD-1 binding protein that antagonizes the activity of PD-1, wherein the heterologous nucleic acid sequence is stably incorporated into the genome of the oncolytic virus.

2. The recombinant oncolytic virus of claim 1, wherein the anti-PD-1 binding protein is selected from the group consisting of a natural ligand, a genetically modified ligand, a recombinant soluble domain of a natural receptor and a modified version thereof, a peptide ligand, a polypeptide ligand, an antibody molecule and fragments and derivatives thereof, and an antibody-like molecule.

3. The recombinant oncolytic virus of claim 1, wherein the anti-PD-1 binding protein is an anti-PD-1 antibody.

4. The recombinant oncolytic virus of claim 1 wherein the oncolytic virus is selected from the group consisting of vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), retrovirus, reovirus, measles virus, Sinbis virus, influenza virus, herpes simplex virus (HSV), vaccinia virus, and adenovirus.

5. The recombinant oncolytic virus of claim 4, wherein the virus is HSV.

7. The recombinant oncolytic virus of claim 5, wherein the HSV genome has a mutation in each ICP34.5 locus such that the HSV cannot express a functional ICP34.5 gene product.

8. The recombinant oncolytic virus of claim 5, wherein the HSV is HSV-2 and the HSV-2 genome encodes a modified ICP10 polypeptide having ribonucleotide reductase activity, but lacking protein kinase activity.

9. The recombinant oncolytic virus of claim 8, wherein the modified ICP10 polypeptide has a deletion in the protein kinase domain of ICP10.

12. The recombinant oncolytic virus of claim 1 further comprising a gene encoding an immunomodulatory protein selected from the group consisting of:

tumor necrosis factor, interferon alpha, interferon gamma, IL-2, IL-12, IL-15, IL-24, and GM-CSF.

13. The recombinant oncolytic virus of claim 4, wherein the virus is a vaccinia virus.

14. The recombinant oncolytic virus of claim 13, wherein the virus comprises an inactivating mutation in a thymidine kinase (TK) gene to produce a negative TK phenotype.

15. The recombinant oncolytic virus of claim 13, wherein the vaccinia virus does not express functional vaccinia growth factor (VGF).

16. The recombinant oncolytic virus of claim 13, wherein the vaccinia virus does not express functional B13R.

17. The recombinant oncolytic virus of claim 13 further comprising a gene encoding an immunomodulatory protein selected from the group consisting of:

tumor necrosis factor, interferon alpha, interferon gamma, IL-2, IL-12, IL-15, IL-24, and GM-CSF.

18. The recombinant oncolytic virus of claim 1, wherein the heterologous nucleic acid sequence encoding the PD-1 binding agent is operably linked to a CMV promoter.

19. The recombinant oncolytic virus of claim 4, wherein the virus is an adenovirus.

20. A pharmaceutical composition comprising an effective amount of the virus of claim 1 and a pharmaceutically acceptable carrier.

21. The pharmaceutical composition of claim 20, wherein the composition is formulated for parenteral administration.

22. The pharmaceutical composition of claim 20, wherein the composition is formulated for intratumoral administration.

23. A method of treating cancer comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 20.

6. (canceled)

10. (canceled)

11. (canceled)